ACTIVLOR™ 90 – Rapid Activation. Trusted Outcomes.

ACTIVLOR™ 90 (Ticagrelor 90 mg) is a potent, fast-acting P2Y₁₂ receptor antagonist designed to deliver rapid, consistent, and reliable platelet inhibition in patients with acute coronary syndromes (ACS). Unlike prodrugs, ticagrelor provides direct and reversible platelet inhibition, ensuring early onset of action and effective reduction of thrombotic events.

With its rapid activation and predictable antiplatelet effect, ACTIVLOR ™ 90 helps achieve early and sustained platelet suppression, reducing the risk of cardiovascular death, myocardial infarction, and stroke. Its efficacy across a wide range of ACS patients—including those undergoing PCI or conservative management—makes it a cornerstone therapy in modern antiplatelet management.

Backed by robust clinical evidence, proven outcomes, and a well-established safety profile, ACTIVLOR™ 90 offers confidence, consistency, and trust in critical cardiac care.
ACTIVLOR™ 90 stands for speed when seconds matter and outcomes you can rely on.